127 related articles for article (PubMed ID: 36717307)
1. Tocilizumab in the treatment of active chronic humoral rejection resistant to standard therapy.
Chamoun B; Sánchez-Sancho P; Torres IB; Gabaldon A; Perelló M; Sellarés J; Moreso F; Serón D
Nefrologia (Engl Ed); 2022; 42(5):578-584. PubMed ID: 36717307
[TBL] [Abstract][Full Text] [Related]
2. Assessment of Tocilizumab (Anti-Interleukin-6 Receptor Monoclonal) as a Potential Treatment for Chronic Antibody-Mediated Rejection and Transplant Glomerulopathy in HLA-Sensitized Renal Allograft Recipients.
Choi J; Aubert O; Vo A; Loupy A; Haas M; Puliyanda D; Kim I; Louie S; Kang A; Peng A; Kahwaji J; Reinsmoen N; Toyoda M; Jordan SC
Am J Transplant; 2017 Sep; 17(9):2381-2389. PubMed ID: 28199785
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of rituximab and intravenous immunoglobulin therapy in renal transplant recipients with chronic active antibody-mediated rejection.
Hong YA; Kim HG; Choi SR; Sun IO; Park HS; Chung BH; Choi BS; Park CW; Kim YS; Yang CW
Transplant Proc; 2012 Jan; 44(1):182-4. PubMed ID: 22310610
[TBL] [Abstract][Full Text] [Related]
4. Impact of Tocilizumab (Anti-IL-6R) Treatment on Immunoglobulins and Anti-HLA Antibodies in Kidney Transplant Patients With Chronic Antibody-mediated Rejection.
Shin BH; Everly MJ; Zhang H; Choi J; Vo A; Zhang X; Huang E; Jordan SC; Toyoda M
Transplantation; 2020 Apr; 104(4):856-863. PubMed ID: 31385933
[TBL] [Abstract][Full Text] [Related]
5. Tocilizumab and Active Antibody-Mediated Rejection in Kidney Transplantation: A Literature Review.
Cabezas L; Jouve T; Malvezzi P; Janbon B; Giovannini D; Rostaing L; Noble J
Front Immunol; 2022; 13():839380. PubMed ID: 35493469
[TBL] [Abstract][Full Text] [Related]
6. Early effects of first-line treatment with anti-interleukin-6 receptor antibody tocilizumab for chronic active antibody-mediated rejection in kidney transplantation.
Lavacca A; Presta R; Gai C; Mella A; Gallo E; Camussi G; Abbasciano I; Barreca A; Caorsi C; Fop F; Messina M; Rossetti M; Biancone L
Clin Transplant; 2020 Aug; 34(8):e13908. PubMed ID: 32415711
[TBL] [Abstract][Full Text] [Related]
7. Durable renal response after combination of bortezomib, corticosteroids, rituximab, and plasmapheresis for late antibody-mediated renal transplant rejection
.
Ding Y; Francis J; Gautam A; Pelletier L; Sanchorawala V; Quillen K
Clin Nephrol; 2018 Apr; 89(4):252-259. PubMed ID: 29208204
[TBL] [Abstract][Full Text] [Related]
8. Response to treatment and long-term outcomes in kidney transplant recipients with acute T cell-mediated rejection.
Bouatou Y; Viglietti D; Pievani D; Louis K; Duong Van Huyen JP; Rabant M; Aubert O; Taupin JL; Glotz D; Legendre C; Loupy A; Lefaucheur C
Am J Transplant; 2019 Jul; 19(7):1972-1988. PubMed ID: 30748089
[TBL] [Abstract][Full Text] [Related]
9. Tocilizumab for the treatment of chronic antibody mediated rejection in kidney transplant recipients.
Khairallah P; Robbins-Juarez S; Patel S; Shah V; Toma K; Fernandez H; Dube GK; King K; Mohan S; Husain SA; Morris H; Crew RJ
Clin Transplant; 2023 Jan; 37(1):e14853. PubMed ID: 36398915
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of combination therapy for chronic antibody-mediated rejection in renal transplantation.
Kim MG; Kim YJ; Kwon HY; Park HC; Koo TY; Jeong JC; Jeon HJ; Han M; Ahn C; Yang J
Nephrology (Carlton); 2013 Dec; 18(12):820-6. PubMed ID: 24033843
[TBL] [Abstract][Full Text] [Related]
11. Circulating donor-specific anti-HLA antibodies are a major factor in premature and accelerated allograft fibrosis.
Gosset C; Viglietti D; Rabant M; Vérine J; Aubert O; Glotz D; Legendre C; Taupin JL; Duong Van-Huyen JP; Loupy A; Lefaucheur C
Kidney Int; 2017 Sep; 92(3):729-742. PubMed ID: 28554738
[TBL] [Abstract][Full Text] [Related]
12. Tocilizumab for treatment of chronic active antibody-mediated rejection in kidney transplant recipients.
Boonpheng B; De Castro ICC; Ng YH; Blosser C; Bakthavatsalam R; Gimferrer I; Smith K; Leca N
Clin Transplant; 2023 May; 37(5):e14936. PubMed ID: 36787372
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Value of the Persistence of C1q-Binding Anti-HLA Antibodies in Acute Antibody-Mediated Rejection in Kidney Transplantation.
Bailly E; Anglicheau D; Blancho G; Gatault P; Vuiblet V; Chatelet V; Morelon E; Malvezzi P; Parissiadis A; Tourret J; Guidicelli G; Sayegh J; Mousson C; Grimbert P; Top I; Le Quintrec M; Purgus R; Westeel PF; Proust B; Chabot V; Lebranchu Y; Dehaut F; Büchler M
Transplantation; 2018 Apr; 102(4):688-698. PubMed ID: 29135832
[TBL] [Abstract][Full Text] [Related]
14. Lack of Histological and Molecular Signature Response to Tocilizumab in Kidney Transplants with Chronic Active Antibody Mediated Rejection: A Case Series.
Kumar D; Yakubu I; Safavi F; Levy M; Moinuddin I; Kimball P; Kamal L; King A; Massey D; Halloran P; Gupta G
Kidney360; 2020 Jul; 1(7):663-670. PubMed ID: 35372943
[TBL] [Abstract][Full Text] [Related]
15. Do anti-IL-6R blockers have a beneficial effect in the treatment of antibody-mediated rejection resistant to standard therapy after kidney transplantation?
Massat M; Congy-Jolivet N; Hebral AL; Esposito L; Marion O; Delas A; Colombat M; Faguer S; Kamar N; Del Bello A;
Am J Transplant; 2021 Apr; 21(4):1641-1649. PubMed ID: 33141487
[TBL] [Abstract][Full Text] [Related]
16. Belatacept in renal transplant recipient with mild immunologic risk factor: A pilot prospective study (BELACOR).
Leibler C; Matignon M; Moktefi A; Samson C; Zarour A; Malard S; Boutin E; Pilon C; Salomon L; Natella PA; Durrbach A; Robert T; Canoui-Poitrine F; Grimbert P
Am J Transplant; 2019 Mar; 19(3):894-906. PubMed ID: 30582270
[TBL] [Abstract][Full Text] [Related]
17. Failure to remove de novo donor-specific HLA antibodies is influenced by antibody properties and identifies kidney recipients with late antibody-mediated rejection destined to graft loss - a retrospective study.
Cioni M; Nocera A; Tagliamacco A; Basso S; Innocente A; Fontana I; Magnasco A; Trivelli A; Klersy C; Gurrado A; Ramondetta M; Boghen S; Catenacci L; Verrina E; Garibotto G; Ghiggeri GM; Cardillo M; Ginevri F; Comoli P
Transpl Int; 2019 Jan; 32(1):38-48. PubMed ID: 30076765
[TBL] [Abstract][Full Text] [Related]
18. Treatment of chronic antibody mediated rejection with intravenous immunoglobulins and rituximab: A multicenter, prospective, randomized, double-blind clinical trial.
Moreso F; Crespo M; Ruiz JC; Torres A; Gutierrez-Dalmau A; Osuna A; Perelló M; Pascual J; Torres IB; Redondo-Pachón D; Rodrigo E; Lopez-Hoyos M; Seron D
Am J Transplant; 2018 Apr; 18(4):927-935. PubMed ID: 28949089
[TBL] [Abstract][Full Text] [Related]
19. Treatment of antibody-mediated rejection with double-filtration plasmapheresis, low dose IVIg plus rituximab after kidney transplantation.
Naciri Bennani H; Daligault M; Noble J; Bardy B; Motte L; Giovannini D; Emprou C; Fiard G; Imerzoukene F; Bourdin A; Masson D; Janbon B; Malvezzi P; Rostaing L; Jouve T
J Clin Apher; 2021 Aug; 36(4):584-594. PubMed ID: 33783868
[TBL] [Abstract][Full Text] [Related]
20. Management of Chronic Active Antibody-Mediated Rejection in Renal Transplant Recipients: Single-Center Experience.
Nair P; Gheith O; Al-Otaibi T; Mostafa M; Rida S; Sobhy I; Halim MA; Mahmoud T; Abdul-Hameed M; Maher A; Emam M
Exp Clin Transplant; 2019 Jan; 17(Suppl 1):113-119. PubMed ID: 30777534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]